Mineralys Therapeutics to Participate in Upcoming Investor Conferences
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company specializing in treatments for hypertension and chronic kidney disease, has announced its participation in three upcoming investor conferences. The company will engage in fireside chats at the Guggenheim Healthcare Innovation Conference (November 12, 4:00pm EST), Stifel Healthcare Conference (November 19, 10:20am EST), and Evercore ISI HealthCONx Conference (December 4, 4:15pm EST). Live webcasts will be available on the company's website under the Investor Relations section, with replays accessible for approximately 90 days.
Mineralys Therapeutics (NASDAQ: MLYS), una società biofarmaceutica in fase clinica specializzata in trattamenti per l'ipertensione e la malattia renale cronica, ha annunciato la sua partecipazione a tre prossime conferenze per investitori. La società parteciperà a conversazioni informali durante la Guggenheim Healthcare Innovation Conference (12 novembre, ore 16:00 EST), la Stifel Healthcare Conference (19 novembre, ore 10:20 EST) e la Evercore ISI HealthCONx Conference (4 dicembre, ore 16:15 EST). Saranno disponibili trasmissioni dal vivo sul sito web dell'azienda nella sezione Relazioni con gli Investitori, con le registrazioni accessibili per circa 90 giorni.
Mineralys Therapeutics (NASDAQ: MLYS), una compañía biofarmacéutica en etapa clínica especializada en tratamientos para la hipertensión y la enfermedad renal crónica, ha anunciado su participación en tres próximas conferencias para inversores. La compañía participará en charlas íntimas en la Guggenheim Healthcare Innovation Conference (12 de noviembre, 4:00 p.m. EST), la Stifel Healthcare Conference (19 de noviembre, 10:20 a.m. EST) y la Evercore ISI HealthCONx Conference (4 de diciembre, 4:15 p.m. EST). Se podrán acceder a transmisiones en vivo en el sitio web de la compañía en la sección de Relaciones con Inversores, con repeticiones accesibles durante aproximadamente 90 días.
Mineralys Therapeutics (NASDAQ: MLYS)는 고혈압 및 만성 신장 질환 치료에 특화된 임상 단계의 생명공학 회사로, 향후 세 개의 투자자 회의에 참석할 것임을 발표했습니다. 이 회사는 구겐하임 헬스케어 혁신 회의 (11월 12일, 오후 4:00 EST), 스티펠 헬스케어 회의 (11월 19일, 오전 10:20 EST) 및 에버코어 ISI 헬스CONx 회의 (12월 4일, 오후 4:15 EST)에서 간담회에 참여할 예정입니다. 회사의 웹사이트의 투자자 관계 섹션에서 생중계를 확인할 수 있으며, 약 90일 동안 다시 보기 가능할 것입니다.
Mineralys Therapeutics (NASDAQ: MLYS), une entreprise biopharmaceutique en phase clinique spécialisée dans les traitements de l'hypertension et de la maladie rénale chronique, a annoncé sa participation à trois conférences d'investisseurs à venir. L'entreprise participera à des discussions informelles lors de la Guggenheim Healthcare Innovation Conference (12 novembre, 16h00 EST), de la Stifel Healthcare Conference (19 novembre, 10h20 EST) et de la Evercore ISI HealthCONx Conference (4 décembre, 16h15 EST). Des webcasts en direct seront disponibles sur le site web de l'entreprise dans la section Relations Investisseurs, avec des rediffusions accessibles pendant environ 90 jours.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in klinischer Entwicklungsphase, das sich auf Behandlungen für Bluthochdruck und chronische Nierenerkrankungen spezialisiert hat, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen angekündigt. Das Unternehmen wird an informellen Gesprächen während der Guggenheim Healthcare Innovation Conference (12. November, 16:00 EST), der Stifel Healthcare Conference (19. November, 10:20 EST) und der Evercore ISI HealthCONx Conference (4. Dezember, 16:15 EST) teilnehmen. Live-Übertragungen werden auf der Website des Unternehmens im Bereich Investor Relations verfügbar sein, mit Aufzeichnungen, die etwa 90 Tage lang zugänglich sind.
- None.
- None.
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in fireside chats at three upcoming investor conferences.
| Guggenheim Healthcare Innovation Conference: | |
| Date: | Tuesday, November 12, 2024 |
| Time: | 4:00pm EST |
| Format: | Fireside Chat |
| Webcast Link | |
| Stifel Healthcare Conference: | |
| Date: | Tuesday, November 19, 2024 |
| Time: | 10:20am EST |
| Format: | Fireside Chat |
| Webcast Link | |
| Evercore ISI HealthCONx Conference | |
| Date: | Wednesday, December 4, 2024 |
| Time: | 4:15pm EST |
| Format: | Fireside Chat |
| Webcast Link | |
Live webcasts of the fireside chats can be accessed under “News and Events” on the Investor Relations section of the Mineralys website at www.mineralystx.com. A replay of the webcasts will be available on the Company’s website for approximately 90 days.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
What investor conferences is Mineralys Therapeutics (MLYS) attending in late 2024?
When is Mineralys Therapeutics (MLYS) presenting at the Guggenheim Healthcare Conference?
How long will the webcasts of Mineralys Therapeutics (MLYS) investor conferences be available?
What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?
